Regenerative Medicine

Quote






I AGREE 100% about Shire over paying. Matt P is prob shitting a break knowing they have no chance to make the kind of money we bought ABH for. That price was completely inflated!! Good luck trying to hit your numbers and good luck lasting much longer than a year!
 






























Curtis B is the worse manager in the history of sales management. At best, he should be working at Texas Stadium selling hotdogs. Just disgusting the people above that have put these clowns in management positions.
 












After the divestiture of Dermagraft - per our incoming CEO - the company that buys us for 1/3 of what Shire paid will be laying all of us off. Put a fork in Dermagraft. It's done.
 






Please don't let this be true. I was waxed last year from another company and moved up here for this position. I was told that once you are with shire you are part of the family and you have a job for life
 






Anonymous said:
Please don't let this be true. I was waxed last year from another company and moved up here for this position. I was told that once you are with shire you are part of the family and you have a job for life
Click to expand...

That was true when the family working in Chesterbrook had a F'ing clue what they were doing. This family, couldn't give an F about you or how far you've moved.
 






"Ornskov also said that divesting Dermagraft, a treatment for diabetic foot ulcers, isn’t out of the question, this person said. Shire acquired the product with its $750 million purchase of Advanced Biohealing Inc. in May 2011. The company abandoned efforts to develop Dermagraft for leg ulcers in August 2011 after it failed in a clinical trial. Sales of Dermagraft dropped 65 percent to $19 million in the fourth quarter, Shire said Feb. 14."
 






April 26, 2012 by MassDevice staff

Shire faces civil and criminal investigations by the U.S. Justice Dept. and a pair of U.S. Attorneys' Offices for marketing practices related to its DermaGraft diabetic foot ulcer treatment.


British biotech Shire*(NSDQ:SHPGY) is under investigation by the U.S. Justice Dept. for marketing practices for its Dermagraft diabetic foot ulcer treatment, according to regulatory filings.
 






Anonymous said:
"Ornskov also said that divesting Dermagraft, a treatment for diabetic foot ulcers, isn’t out of the question, this person said. Shire acquired the product with its $750 million purchase of Advanced Biohealing Inc. in May 2011. The company abandoned efforts to develop Dermagraft for leg ulcers in August 2011 after it failed in a clinical trial. Sales of Dermagraft dropped 65 percent to $19 million in the fourth quarter, Shire said Feb. 14."
Click to expand...

This is Bs. Why do you people always need to spread fear and hate. If RM was going down why would they hire me at top dollar and all the reps I hired at top dollar too. This was just six months ago
 












Some former super sales people will get called out. Many examples in medical device lately. You can run but you cannot hide. Hope the extra couple of bucks were worth it.
 






Anonymous said:
This is Bs. Why do you people always need to spread fear and hate. If RM was going down why would they hire me at top dollar and all the reps I hired at top dollar too. This was just six months ago
Click to expand...

When BMS buys you out (Wall street Jounal 3/4/13), do you think they will care what your starting pay is or when you were hired ? I hope you didn't leave a good job for this one.
 
























Top Bottom
Back
Quote